Proton Therapy For Lymphomas: Current State Of The Art.
Hodgkin
lymphoma
proton therapy
radiotherapy
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
06
2019
accepted:
13
09
2019
entrez:
22
10
2019
pubmed:
22
10
2019
medline:
22
10
2019
Statut:
epublish
Résumé
The combination of brief chemo-radiotherapy provides high cure rates and represents the first line of treatment for many lymphoma patients. As a result, a high proportion of long-term survivors may experience treatment-related toxic events many years later. Excess and unintended radiation dose to organs at risk (particularly heart, lungs and breasts) may translate in an increased risk of cardiovascular events and second cancers after a few decades. Minimizing dose to organs at risk is thus pivotal to restrain the risk of long-term complications. Proton therapy, with its peculiar physic properties, may help to better spare organs at risk and consequently to reduce toxicities especially in patients receiving mediastinal radiotherapy. Herein, we review the physical basis of proton therapy and the rationale for its implementation in lymphoma patients, with a detailed description of the clinical data. We also discuss the potential disadvantages and uncertainties of protons that may limit their application and critically review the dosimetric studies comparing the risk of late complications between proton and photon radiotherapy.
Identifiants
pubmed: 31632057
doi: 10.2147/OTT.S220730
pii: 220730
pmc: PMC6781741
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8033-8046Informations de copyright
© 2019 Ricardi et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work
Références
J Clin Oncol. 2010 Sep 20;28(27):4199-206
pubmed: 20713848
Ann Oncol. 2017 Sep 01;28(9):2179-2184
pubmed: 28911093
Pract Radiat Oncol. 2019 Nov;9(6):426-434
pubmed: 31128302
Semin Radiat Oncol. 2018 Jun;28(3):256-263
pubmed: 29933885
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):167-74
pubmed: 20643518
Acta Oncol. 2016 Nov;55(11):1378-1380
pubmed: 27579554
Radiother Oncol. 2019 Sep;138:52-58
pubmed: 31146071
Ann Oncol. 2014 Aug;25(8):1622-8
pubmed: 24827123
Ann Oncol. 2013 Aug;24(8):2113-8
pubmed: 23619032
Blood. 2018 Oct 18;132(16):1635-1646
pubmed: 30108066
Cancer Radiother. 2016 Apr;20(2):98-103
pubmed: 26992750
Radiother Oncol. 2014 Mar;110(3):441-7
pubmed: 24188865
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):43-45
pubmed: 27084623
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):530-540
pubmed: 29681481
J Clin Oncol. 2003 Oct 1;21(19):3601-8
pubmed: 12913100
J Clin Oncol. 2014 Apr 20;32(12):1188-94
pubmed: 24637998
Phys Med Biol. 2014 Jul 7;59(13):3431-52
pubmed: 24889215
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):169-74
pubmed: 25754634
Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):220-230
pubmed: 32866566
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):62-69
pubmed: 27084629
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):433-45
pubmed: 24321783
Cancer J. 2014 Nov-Dec;20(6):387-92
pubmed: 25415683
Phys Med Biol. 2014 Nov 21;59(22):R419-72
pubmed: 25361443
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):854-62
pubmed: 23790512
Radiother Oncol. 2018 Jun;127(3):481-486
pubmed: 29729845
Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1429-38
pubmed: 11286851
Acta Oncol. 2016 Sep - Oct;55(9-10):1132-1138
pubmed: 27332881
Pediatr Blood Cancer. 2016 Sep;63(9):1522-6
pubmed: 27149120
Radiother Oncol. 2017 Oct;125(1):41-47
pubmed: 28838605
Leuk Lymphoma. 2015;56(9):2608-12
pubmed: 25669925
N Engl J Med. 2011 Jul 21;365(3):203-12
pubmed: 21774708
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):260-7
pubmed: 22014950
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):553-562
pubmed: 30625409
Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):297-303
pubmed: 23910709
Semin Oncol. 2019 Jun;46(3):193-201
pubmed: 31395286
Strahlenther Onkol. 2019 Jul;195(7):677-687
pubmed: 30972453
Blood. 2007 Mar 1;109(5):1878-86
pubmed: 17119114
Leuk Lymphoma. 2015 Jul;56(7):2019-24
pubmed: 25315071
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):449-55
pubmed: 22386373
Pract Radiat Oncol. 2019 May;9(3):179-187
pubmed: 30708133
Acta Oncol. 2013 Oct;52(7):1559-65
pubmed: 24047340
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):175-82
pubmed: 25863764
N Engl J Med. 2015 Apr 23;372(17):1598-607
pubmed: 25901426
N Engl J Med. 2015 Dec 24;373(26):2499-511
pubmed: 26699166
Strahlenther Onkol. 2013 Jan;189(1):54-61
pubmed: 23161118
Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1053-1059
pubmed: 24928256
Phys Med Biol. 2015 Feb 21;60(4):1717-40
pubmed: 25650520
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):161-8
pubmed: 25863763
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1173-80
pubmed: 19386423
Phys Med Biol. 1984 May;29(5):553-66
pubmed: 6330772
J Clin Oncol. 2016 Jan 20;34(3):235-43
pubmed: 26573075
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):892-4
pubmed: 25832682
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):49-58
pubmed: 24725689
Ann Oncol. 2017 Sep 1;28(9):2049-2050
pubmed: 28911077
Acta Oncol. 2019 Jan;58(1):95-104
pubmed: 30280626
Radiat Oncol. 2018 Jul 3;13(1):122
pubmed: 29970105
Curr Hematol Malig Rep. 2014 Sep;9(3):203-11
pubmed: 24842407